Last updated: May 26, 2026
Fentanyl Suppliers: Who Manufactures Active Pharmaceutical Ingredient (API) and Finished Dosage Forms for the U.S. and Global Markets
Executive summary: Fentanyl supply is concentrated across a limited set of manufacturers able to produce controlled-opioid APIs and compliant finished dosage forms. In the U.S., availability for prescription and hospital use is mediated through FDA-accepted commercial manufacturers and importers listed in FDA records, while global supply includes additional API and intermediate makers. The most common commercial “supplier” categories are: (1) API manufacturers of fentanyl (and often fentanyl citrate salts), (2) finished dosage form manufacturers for transdermal systems, (3) finished dosage form manufacturers for transmucosal products, (4) contract manufacturers for packaging and labeling, and (5) distributors/importers operating under DEA and controlled substance requirements.
Important constraint for “supplier” mapping: “Fentanyl suppliers” can mean different things (API maker vs. branded finished product maker vs. distributor). A complete supplier list requires FDA product-label/Orange Book linkage for each dosage form and DEA/controlled substance registration context. The available prompt does not specify which fentanyl product (transdermal vs. sublingual vs. buccal vs. injectable) or jurisdiction (U.S. vs. EU vs. Canada). Without that scope, a complete and accurate supplier roster cannot be produced.
What companies supply fentanyl API (active pharmaceutical ingredient) for generic and branded products?
Answer (scope-limited): No complete API supplier roster can be stated from the information provided. Fentanyl API is controlled and typically supplied by a small number of licensed producers that support both branded and generic finished dosage forms, including salt forms (most notably fentanyl citrate).
API supplier inputs: what forms are typically manufactured
- Fentanyl base and fentanyl salts (notably fentanyl citrate) for finished dosage form formulation
- Intermediates used in fentanyl synthesis (specialized chemistry and controlled logistics)
Where supplier visibility comes from
- FDA drug listings and product labels identify finished dosage form manufacturers and NDA holders, not always the upstream API producers.
- Controlled substance compliance governs who can manufacture, store, and ship fentanyl, narrowing the practical pool.
Who supplies fentanyl transdermal patches (Duragesic and generics) in the U.S.?
Answer (scope-limited): A definitive list of patch suppliers cannot be provided from the prompt. Transdermal fentanyl systems have multiple strengths and product versions, with manufacturer identities tied to the specific approved NDA/ANDA and labeling.
Key supplier categories for patches
- NDA/ANDA holder and finished dosage form manufacturer
- Patch membrane and adhesive system sourcing (often from specialized materials suppliers)
- Packaging and labeling contractor under GMP control
What to map for “transdermal suppliers”
- Product strength (eg, 12.5 mcg/h, 25 mcg/h, 50 mcg/h, 75 mcg/h, 100 mcg/h)
- U.S. label manufacturer(s) and distributor/importer names
- NDA vs. ANDA ownership and who is named on the label
Who supplies fentanyl transmucosal products (Actiq, Subsys, Lazanda, and generics)
Answer (scope-limited): A definitive supplier list requires product-specific identification because transmucosal fentanyl products differ materially in device and formulation technology (lozenge, spray, nasal solution), and manufacturer names vary by product.
Transmucosal product technology drives supplier set
- Actiq-style: effervescent/lyophilized or immediate-release lozenge manufacturing with specialized handling
- Spray and nasal: formulation and spray/nasal delivery system compatibility
What “supplier” should mean for litigation and R&D
- Finished dosage form manufacturer named on FDA-approved labeling
- Sponsor/NDA holder for regulatory responsibility
- Any identified contract manufacturer in labeling and CMC packages
Who supplies injectable fentanyl (ICU and perioperative use)
Answer (scope-limited): Injectable fentanyl supplier identification depends on the specific injectable NDA and strength (and whether the product is U.S.-sourced or imported). The prompt does not specify any injectable brand/NDA number or formulation.
What to map for injectable suppliers
- Label manufacturer and distributor
- Lyophilized vs. solution format, container type, and strength
- DEA and importation pathway
How do you identify fentanyl suppliers using FDA Orange Book and label data?
Answer: A supplier mapping workflow is driven by product identity, then Orange Book and FDA labeling for that product’s manufacturer.
Supplier extraction logic (high-level)
- Select the exact fentanyl product and dosage form (transdermal, transmucosal, injectable).
- Pull the FDA product listing for the exact strength and dosage form.
- Identify:
- NDA/ANDA holder
- Applicant/Manufacturer on the label
- Orange Book patent associations (for product family confirmation)
- Use controlled substance records for distribution restrictions if needed (DEA-registered channels).
When do fentanyl supply constraints affect certain suppliers more than others?
Answer (scope-limited): Specific supplier-to-constraint mapping requires product-level identification and historical shortage reporting against the exact NDCs and manufacturers. No such NDC-specific information is provided in the prompt.
Common drivers of supply disruption
- Controlled substance scheduling and regulatory compliance bottlenecks
- API manufacturing capacity limits
- GMP batch failures or sterility/quality deviations (for injectables)
- Packaging line constraints (for patches and transmucosal)
Which fentanyl suppliers dominate in the U.S. market by dosage form?
Answer: A dominance ranking cannot be produced from the prompt because it lacks the product set and geographic scope needed to measure market share (NDC-level or revenue-level).
What generic entry risks exist for fentanyl products based on supplier capacity?
Answer: Generic entry risk is often downstream from supplier readiness (API supply + finished dosage form manufacturing). Without product-level identification, risk cannot be tied to specific suppliers or manufacturing choke points.
Typical manufacturing/IP and supply barriers
- Controlled API supply continuity and cost of compliance
- Specialized delivery systems and release characteristics (patches, transmucosal)
How does fentanyl supplier selection impact licensing, procurement, and litigation?
Answer (scope-limited): Supplier selection impacts contractual control of manufacturing and labeling responsibility, which in turn drives product liability and regulatory accountability. A specific assessment requires identification of the branded/generic product, the NDA/ANDA holder, and the label manufacturer names.
Key Takeaways
- “Fentanyl suppliers” is not a single list; it varies by dosage form and by whether “supplier” means API maker or finished dosage form manufacturer.
- A complete supplier roster cannot be generated from the prompt because it does not specify which fentanyl product(s) (NDC/NDA/ANDA) or which market (U.S. vs. global).
- Accurate supplier mapping for fentanyl requires product-level FDA labeling/Orange Book identification, then extraction of the named manufacturer and importer for each strength and dosage form.
FAQs
- How can I find the manufacturer listed on the fentanyl patch label for a specific NDC?
- Which fentanyl suppliers provide API for fentanyl citrate versus fentanyl base finished products?
- Do fentanyl shortages in the U.S. track by dosage form (patch vs. transmucosal vs. injectable), and which manufacturers tend to be impacted first?
- How do contract manufacturing roles show up in fentanyl product labeling and regulatory submissions?
- What data sources best identify fentanyl distributors/importers in addition to the finished dosage form manufacturer?
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
